HLS Therapeutics Inc has seen a slight decline in its stock performance this week, alongside some recent financial updates.
This week, HLS Therapeutics Inc (HLS.TO) experienced a 3.06% decrease in stock price, closing at C$4.00. While the company reported its Q1 2026 financial results, the market's reaction has been muted, reflecting broader investor sentiment.
Investor takeaway: Investors should consider the recent financial performance and product launches as potential indicators of future growth, while also keeping an eye on the overall market conditions affecting healthcare stocks.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.29
+76.9% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Reports Q1 2026 Revenue of $12.9 Million
The company's revenue has grown by 2% year-over-year, indicating a modest upward trend amidst broader challenges.
Bull case
The launch of NILEMDO™ in Canada and the steady growth in Vascepa sales could position HLS Therapeutics for improved revenue streams, which may attract investor interest.
Bear case
Despite these positive developments, concerns about profitability and market competition are affecting the stock's current performance, which could hinder its recovery.
Recent Price Action
Advertisement
HLS Therapeutics Inc (HLS.TO) closed at C$4.00, unchanged on the day, but down 3.06% over the week. The stock has experienced a decline of 4.19% over the past month and is down 15.05% year-to-date.
Company News and Financial Updates
Recently, HLS Therapeutics reported its Q1 2026 financial results, noting revenue of $12.9 million, which is a 2% increase year-over-year. The company also highlighted a 15% growth in Vascepa net sales. Additionally, HLS announced the Canadian launch of NILEMDO™, a new therapy aimed at patients with high LDL-cholesterol who are statin intolerant. The company reaffirmed its 2026 financial guidance, targeting revenue between $56 million and $60 million.
Technical Picture
From a technical standpoint, HLS is currently trading below its 50-day moving average of C$4.33 and its 200-day moving average of C$4.64, indicating a bearish trend. The stock's 52-week range is C$4.00 to C$5.76, with the current price at the lower end of this range. HLS has a beta of 0.86, suggesting lower volatility compared to the market. The latest trading volume was 4,774 shares, significantly below the 20-day average of 7,653 shares, indicating reduced investor interest.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
